Literature DB >> 14685775

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.

R P Baumann1, K Shyam, P G Penketh, J S Remack, T P Brent, A C Sartorelli.   

Abstract

PURPOSE: VNP40101M (1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine) is a sulfonylhydrazine prodrug that possesses broad spectrum antitumor efficacy in murine models. VNP40101M activation generates chloroethylating species that alkylate DNA at the O(6)-position of guanine, and a carbamoylating agent, methyl isocyanate, which inhibits O(6)-alkylguanine-DNA alkyltransferase (AGT) in model systems. We determined whether expression of AGT in Chinese hamster ovary (CHO) cells decreased sensitivity to VNP40101M and explored the mechanism of VNP40101M cytotoxicity by employing analogs of VNP40101M that generate reactive intermediates with either carbamoylating or chloroethylating activity.
METHODS: AGT was overexpressed in CHO cells by transfection with an expression vector containing the human AGT gene. Cell lines expressing AGT were employed in clonogenic assays to determine the cytotoxicity of VNP40101M and its analogs.
RESULTS: VNP40101M was more active against AGT-expressing CHO cells than 90CE (1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine), a chloroethylating generator devoid of carbamoylating activity. Furthermore, the greater the degree of AGT expression the more resistance to VNP40101M cytotoxicity. Combination chemotherapy experiments support the conclusions that methyl isocyanate and the chloroethylating species generated from the activation of VNP40101M function synergistically to kill cells.
CONCLUSIONS: The findings support the concept that alkylation of the O(6)-position of guanine residues in DNA is the predominant lesion created by VNP40101M, and that methyl isocyanate resulting from the base-catalyzed activation of VNP40101M inhibits AGT and presumably other enzymes involved in DNA repair, thereby enhancing the yield of the DNA G-C interstrand crosslinks responsible for the antitumor activity of this agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685775     DOI: 10.1007/s00280-003-0739-0

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.

Authors:  Rui Zhu; Mao-Chin Liu; Mei-Zhen Luo; Philip G Penketh; Raymond P Baumann; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  J Med Chem       Date:  2011-10-17       Impact factor: 7.446

2.  pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.

Authors:  Philip G Penketh; Richard A Finch; Rachel Sauro; Raymond P Baumann; Elena S Ratner; Krishnamurthy Shyam
Journal:  Chem Biol Drug Des       Date:  2017-07-17       Impact factor: 2.817

3.  1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.

Authors:  Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Sara Rockwell; Alan C Sartorelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-17       Impact factor: 11.205

4.  Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.

Authors:  Kimiko Ishiguro; Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

5.  Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

Authors:  Sara Rockwell; Yanfeng Liu; Helen A Seow; Kimiko Ishiguro; Raymond P Baumann; Philip G Penketh; Krishnamurthy Shyam; Oluwatoyin M Akintujoye; Peter M Glazer; Alan C Sartorelli
Journal:  Int J Radiat Biol       Date:  2011-12-20       Impact factor: 2.694

6.  Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.

Authors:  Kimiko Ishiguro; Yong-Lian Zhu; Krishnamurthy Shyam; Philip G Penketh; Raymond P Baumann; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2010-07-21       Impact factor: 5.858

7.  Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine.

Authors:  Rui Zhu; Raymond P Baumann; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  J Med Chem       Date:  2013-01-23       Impact factor: 7.446

8.  Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.

Authors:  Philip G Penketh; Raymond P Baumann; Kimiko Ishiguro; Krishnamurthy Shyam; Helen A Seow; Alan C Sartorelli
Journal:  Leuk Res       Date:  2008-05-13       Impact factor: 3.156

9.  Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.

Authors:  Stephen T Keir; Christopher L Morton; Catherine Billups; Malcolm A Smith; Peter J Houghton; Sridharan Gururangan
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

10.  Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine.

Authors:  Kevin P Rice; Edmund J Klinkerch; Scott A Gerber; Tyler R Schleicher; Tara J Kraus; Christopher M Buros
Journal:  Mol Cell Biochem       Date:  2012-08-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.